Table 3 Comparison of the proportion of the selected chemotherapy regimens, dose-reduction, and skip administration
|  | All patients | Cisplatin-eligible (eGFR ≥60 mL/min/1.73m2) | Cisplatin-ineligible (eGFR < 60 mL/min/1.73 m2) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Cisplatin-eligible (n = 119) | Cisplatin-ineligible (n = 125) | p | Bilateral functioning kidneys (n = 83) | Solitary functioning kidney (n = 36) | p | Bilateral functioning kidneys (n = 45) | Solitary functioning kidney (n = 80) | p | ||
Chemotherapy | GC | 48 (40.3%) | 55 (44.0%) | 0.56 | 35 (42.2%) | 13 (36.2%) | 0.530 | 24 (53.3%) | 31 (38.8%) | 0.160 |
MVAC | 52 (43.6%) | 46 (36.8%) | 0.27 | 37 (44.6%) | 15 (41.6%) | 0.760 | 14 (31.1%) | 32 (40.0%) | 0.110 | |
MEC | 16 (13.4%) | 19 (15.2%) | 0.70 | 9 (10.8%) | 7 (19.4%) | 0.210 | 4 (8.9%) | 15 (18.7%) | 0.140 | |
Gemcitabine + Cisplatin + Docetaxel | 3 (2.5%) | 5 (4.0%) | 0.51 | 2 (2.4%) | 1 (2.8%) | 0.900 | 3 (6.7%) | 2 (2.5%) | 0.850 | |
Cisplatin dose reduction | ||||||||||
 all courses | Yes | 10 (8.4%) | 42 (33.6%) | < 0.001 | 6 (7.2%) | 4 (11.1%) | 0.480 | 16 (35.5%) | 26 (32.5%) | 0.730 |
 1st course | Yes | 9/119 (7.5%) | 48/125 (38.4%) | < 0.001 | 6/83 (7.2%) | 3/36 (8.3%) | 0.834 | 16/45 (35.5%) | 32/80 (39.9%) | 0.623 |
99-80% | 8/119 (6.7%) | 15/125 (12.0%) | 0.158 | 5/83 (6.0%) | 3/36 (8.3%) | 0.644 | 5/45 (11.1%) | 10/80 (12.5%) | 0.810 | |
<  80% | 1/119 (0.8%) | 33/125 (26.4%) | < 0.001 | 1/83 (1.2%) | 0/36 (0.0%) | 0.508 | 11/45 (24.4%) | 22/80 (27.5%) | 0.709 | |
 2nd course | Yes | 8/104 (7.7%) | 39/110 (35.3%) | < 0.001 | 5/72 (8.3%) | 3/32 (9.3%) | 0.667 | 13/42 (30.8%) | 26/68 (38.1%) | 0.437 |
99-80% | 7/104 (6.7%) | 9/110 (8.1%) | 0.686 | 4/72 (6.9%) | 3/32 (9.3%) | 0.473 | 2/42 (4.7%) | 7/68 (10.2%) | 0.303 | |
<  80% | 1/104 (1.0%) | 30/110 (27.2%) | < 0.001 | 1/72 (1.4%) | 0/32 (0.0%) | 0.500 | 11/42 (26.1%) | 19/68 (27.9%) | 0.841 | |
 3rd course | Yes | 4/81 (4.9%) | 23/82 (28.0%) | < 0.001 | 2/54 (3.8%) | 2/27 (7.4%) | 0.468 | 6/24 (24.9%) | 17/58 (29.2%) | 0.690 |
99-80% | 3/81 (3.7%) | 7/82 (8.5%) | 0.198 | 1/54 (1.9%) | 2/27 (7.4%) | 0.212 | 1/24 (4.1%) | 6/58 (10.3%) | 0.362 | |
<  80% | 1/81 (1.2%) | 16/82 (19.5%) | < 0.001 | 1/54 (1.9%) | 0/27 (0.0%) | 0.476 | 5/24 (20.8%) | 11/58 (18.9%) | 0.846 | |
 4th course | Yes | 2/59 (3.4%) | 15/59 (25.4%) | < 0.001 | 0/39 (0.0%) | 2/20 (10.0%) | 0.044 | 4/20 (20.0%) | 12/39 (30.7%) | 0.378 |
99-80% | 2/59 (3.4%) | 6/59 (10.2%) | 0.142 | 0/39 (0.0%) | 2/20 (10.0%) | 0.044 | 1/20 (5.0%) | 5/39 (12.8%) | 0.346 | |
<  80% | 0/59 (0.0%) | 9/59 (15.2%) | < 0.001 | 0/39 (0.0%) | 0/20 (0.0%) | 1.000 | 3/20 (15.0%) | 7/39 (17.9%) | 0.775 | |
Skip | ||||||||||
 all courses | Yes | 65 (54.6%) | 70 (56.0%) | 0.83 | 49 (59.0%) | 16 (44.4%) | 0.140 | 23 (51.1%) | 47 (58.8%) | 0.400 |
No | 54 (45.3%) | 55 (44.0%) | Â | 34 (40.9%) | 20 (55.6%) | Â | 22 (48.9%) | 33 (41.2%) | Â | |
 1st course | day 8 | 8 (6.7%) | 15 (12.0%) | 0.16 | 7 (8.4%) | 1 (2.7%) | 0.250 | 4 (8.9%) | 11 (13.7%) | 0.420 |
day 15 | 54 (45.3%) | 54 (43.2%) | 0.73 | 40 (48.1%) | 14 (38.9%) | 0.340 | 17 (37.7%) | 37 (46.3%) | 0.350 | |
day 22 | 8 (6.7%) | 13 (10.4%) | 0.30 | 6 (7.2%) | 2 (5.6%) | 0.730 | 4 (4.4%) | 9 (11.3%) | 0.680 | |